Mario Tiribelli

Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia

Simona Soverini, Sabrina Colarossi, Alessandra Gnani et al. · Clinical Cancer Research · 2006 · 510 citations · Full text

Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia

Gianantonio Rosti, Francesca Palandri, Fausto Castagnetti et al. · Blood · 2009 · 210 citations · Full text

The efficacy of imatinib mesylate in patients with FIP1L1-PDGFR -positive hypereosinophilic syndrome. Results of a multicenter prospective study

Michele Baccarani, Daniela Cilloni, Michela Rondoni et al. · Haematologica · 2007 · 191 citations · Full text

Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study

Srđan Verstovšek, Aaron T. Gerds, Alessandro M. Vannucchi et al. · The Lancet · 2023 · 164 citations

Hematological Malignancy, Bone Marrow Failure, Momelotinib Versus Danazol +6

Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL)

Paola Secchiero, Elisa Barbarotto, Mario Tiribelli et al. · Blood · 2006 · 156 citations